Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-05T10:51:07.846Z Has data issue: false hasContentIssue false

Evidence needed for treatment strategies in refractory depression

Published online by Cambridge University Press:  02 January 2018

N. Agrawal*
Affiliation:
Clare House, St George's Hospital Medical School, Blackshaw Road, London SW17 0QT, UK
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © 2004 The Royal College of Psychiatrists 

Matthews & Elijamel (Reference Matthews and Eljamel2003) lucidly describe the origin, mechanism and role of vagus nerve stimulation (VNS) in the treatment of refractory depression.

Lack of evidence for strategies to treat refractory depression and lack of perceived options necessitate a fresh look into research on the efficacy of existing treatments and development of new ones. Vagus nerve stimulation may prove to be an effective option and a major advancement, but it is too early even to speculate on recommending it for general use.

The authors state, “If any treatment for chronic, refractory depressive disorder were to offer the prospect of sustained, clinically significant changes in 20-30% of patients, this would represent a major therapeutic advancement”. However, our systematic review of treatment of refractory depression (Reference Stimpson, Agrawal and LewisStimpson et al, 2002) showed an overall placebo response rate of 15% with 95% CI of 7.9-23.4%. This rate is even higher in relatively less chronic depression, reaching up to 30-40% in some trials. Hence, the response rate of 31% in open trials for VNS may largely be due to placebo response and may not result in a satisfactory ‘number needed to treat’ in randomised trials.

The need for further research in this area cannot be overemphasised. Authors have highlighted the difficulty of finding an appropriate control condition. Even if we can satisfy the need for an appropriate placebo control, these trials should not be considered sufficient. For evidence to be robust, any new treatment for refractory depression should at least be compared with the existing active treatments, such as augmentation strategies, in addition to placebo control. Non-inferiority trials without active treatment comparison are not only unethical, they do not help clarify the question of what is the next best strategy in a particular patient with refractory depression. The second half of the past century saw a number of commonly used treatment strategies based only on preliminary evidence. Let us not perpetuate the same mistake in the 21st century.

Footnotes

EDITED BY STANLEY ZAMMIT

References

Matthews, K. & Eljamel, M. S. (2003) Vagus nerve stimulation and refractory depression. Please can you switch me on doctor? British Journal of Psychiatry, 183, 181183.CrossRefGoogle ScholarPubMed
Stimpson, N., Agrawal, N. & Lewis, G. (2002) Randomised controlled trials investigating pharmacological and psychological interventions for treatment refractory depression. Systematic review. British Journal of Psychiatry, 181, 284294.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.